Why is oral semaglutide bioavailability only about one per cent?

This matters because it predicts what a related molecule should do.

This is one of those things that everyone repeats and nobody derives.

This matters practically, not just academically, because it changes what I would do next.

Is the standard explanation correct, and if so, what is the evidence for it?

Start with the administration conditions, because oral agents in this class have strict fasting and water-volume requirements and those requirements are the difference between a dose and nothing.

Gastric residence time and gastric pH both vary with what else is in the stomach, which is the mechanistic reason the conditions are so specific.

A small molecule that activates a class B peptide receptor is a genuinely difficult chemistry problem, which is why this took as long as it did and why the binding site is unusual.

The bioavailability figure for oral semaglutide is published in the regulatory pharmacokinetic review and is around one per cent.

One per cent bioavailability explains the whole difference in tablet strength.

Answer first: oral peptide delivery works by co-formulating an absorption enhancer that transiently raises local gastric pH and permeability, and the resulting bioavailability is low single-figure per cent at best.

Absolute bioavailability is on the order of one per cent, which is why the oral tablet strengths are an order of magnitude above the injectable milligram doses for a comparable exposure.

In practice, dose-equivalence claims between oral and injectable forms of the same molecule should be read as exposure claims rather than milligram claims, because the milligrams are not comparable.

Bioavailability figures are population means around which individuals vary widely, and the variability is the clinically relevant part.

If convenience is the goal, this is the trade being made, and it is a defensible one.

This is answerable precisely from the pharmacokinetic data, and the numbers are more interesting than the marketing.

Between-subject variability in exposure is high, and within-subject variability is high enough that adherence to the administration conditions matters more than it does for almost any other oral drug.

Concretely, orforglipron is a non-peptide small-molecule GLP-1 receptor agonist. It has no absorption enhancer, no food and water restrictions of the same kind, and conventional oral pharmacokinetics.

Research-use material in an oral formulation has no absorption enhancer, no dissolution specification and no meaningful exposure expectation.

Oral peptide and oral small molecule are different technologies with different rules.

edited 10 Dec 2025 by loss_on_drying — added the citation requested in comments

The absorption enhancer is the innovation. Everything else about the oral peptide is the same molecule as the injection.

The administration conditions are not optional: on waking, on an empty stomach, with no more than about half a glass of water, and nothing else by mouth for at least thirty minutes. Food or extra water dilutes the local pH effect and can substantially reduce absorption.

The PIONEER programme evaluated oral semaglutide in type 2 diabetes and is the appropriate citation for that agent.

Do not compare oral and injectable milligrams. Compare exposures.

The relevant distinction is between an oral peptide with an absorption enhancer and a non-peptide small molecule, which needs no enhancer and behaves like a conventional oral drug.

Oral semaglutide is co-formulated with sodium N-(8-(2-hydroxybenzoyl)amino)caprylate, usually written SNAC. It raises pH locally in the stomach, protecting the peptide from pepsin, and transiently increases transcellular permeability at the absorption site.

Nothing here is medical advice.

Empty stomach, small water volume, wait thirty minutes. The conditions are the dose.